Antiglaucoma agents
CA 1084841 A · Owner: Abbott Laboratories · Inventors: Dren, Anthony T.; Bopp, Barbara A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Abstract of the Disclosure A method of reducing intra-ocular pressure in mammalian patients comprising administering to a glaucoma patient a therapeutically effective amount of a compound of the formula, , wherein, in the C ring X is CH2, S, or NR4 where R4 is, H, loweralkyl loweralkenyl, loweralkynyl or loweralkanoyl; n is an integer of 0 to 3; m is an integer of 0 to 3 or the C, ring is a quinuclidine ring ; each R1 is loweralkyl, and, when taken together the substituents R1R1 form oxygen; R2 is a C1-C20 straight or branched chain alkyl cycloalkyl, or, wherein Y is a straight or branched chain alkylene group having from 1 to 10 carbon atoms, and each R5 R6 and R7 are, the same or …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Granted September 2, 1980. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended September 2, 1997.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.